Clinical Trials Results - National Cancer Institute


	Clinical Trials Search Results

	Quick Links


	Director's Corner Dictionary of Cancer Terms NCI Drug Dictionary Funding Opportunities NCI Publications Advisory Boards and Groups Science Serving People Español

Questions about cancer?

	NCI Highlights


	Virtual and Standard Colonoscopy Both Accurate Denosumab May Help Prevent Bone Loss Past Highlights



Results: 1 -10 of 10 Show results per page	View Search Criteria \| Help With Results

Last Modified: 10/31/2007 First Published: 6/1/1997


1.		Phase II Study of Compound 506U78 in Patients with Refractory T-Cell Malignancies

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Closed				21 and below				NCI				POG-9673 CCG-P9673, NCT00002970, P9673

Last Modified: 4/12/2007 First Published: 10/1/1998


2.		Phase II Study of 506U78 for Refractory or Relapsed T-Cell Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Completed				16 and over				NCI				CLB-19801 SWOG-C19801, NCT00003545, CALGB-19801

Last Modified: 1/1/2002 First Published: 12/1/1998


3.		Phase II Study of 506U78 in Patients With Chronic Lymphocytic Leukemia Refractory to Fludarabine and Alkylator Therapy (Summary Last Modified 01/2002)

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Completed				18 and over				NCI, Pharmaceutical / Industry				GW-PGAA2003 CWRU-GLAX-1999, MB-405, NCI-98-C-0164, UCLA-991004701A, NCT00003635

Last Modified: 3/7/2007 First Published: 4/1/2000


4.		Phase II Study of 506U78 in Patients With Cutaneous T-Cell Lymphoma or Refractory or Relapsed Noncutaneous Peripheral T-Cell Lymphoma

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Completed				Under 70				NCI				CALGB-59901 NCT00005080, CALGB-59901

Last Modified: 5/12/2005 First Published: 7/1/2000


5.		Phase II Study of 506U78 in Patients With Recurrent or Refractory Indolent B-Cell Non-Hodgkin's Lymphoma or Peripheral T-Cell Lymphoma

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Completed				16 and over				NCI				MDA-ID-99208 NCI-430, NCT00005950, 430

Last Modified: 2/6/2006 First Published: 7/1/2000


6.		Phase II Study of 506U78 in Patients With Recurrent or Refractory Cutaneous T-Cell Lymphoma

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Completed				16 and over				NCI				MDA-ID-99213 NCI-86, NCT00005982, 86

Last Modified: 1/25/2008 First Published: 7/1/2000


7.		Phase II Study of 506U78 in Patients With Recurrent or Refractory Non-T-Cell Acute Lymphocytic Leukemia

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Closed				16 and over				NCI				SWOG-S0010 NCT00006020, S0010

Last Modified: 1/2/2008 First Published: 5/1/2001


8.		Phase II Pilot Study of Modified Multiagent Berlin-Frankfurt-Muenster-86 Chemotherapy With or Without Nelarabine in Patients With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Completed				1 to 21				NCI				COG-AALL00P2 AALL00P2, NCT00016302

Last Modified: 5/1/2002 First Published: 2/1/2000


9.		Phase I Study of 506U78 in Patients With Hematologic Malignancies and Renal or Hepatic Impairment

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase I				Treatment				Closed				18 and over				NCI				CLB-69803 NCT00004239, CALGB-69803

Last Modified: 10/31/2007 First Published: 5/1/1999


10.		Treatment Referral Center Protocol of 506U78 in Patients with Relapsed or Refractory T-Cell Acute Lymphoblastic Leukemia or T-Cell Lymphoblastic Lymphoma

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	No phase specified				Treatment				Completed				16 and over				NCI				CTEP-TRC-9701 CWRU-TRC-1499, NCT00003837, TRC-9701

Select All on One Page

| | | | | | | |

A Service of the National Cancer Institute